n/N (%) | Reference IFX IV | CT-P13 IV | CT-P13 SC |
---|---|---|---|
Patients achieving a EULAR good response (CRP criteria) | 98/259 (37.8%) | 165/415 (39.8%) | 83/157 (52.9%) |
Patients achieving ACR20 response | 179/261 (68.6%) | 318/418 (76.1%) | 142/161 (88.2%) |
Patients achieving ACR50 response | 103/261 (39.5%) | 195/418 (46.7%) | 106/161 (65.8%) |
Patients achieving ACR70 response | 47/261 (18.0%) | 97/418 (23.2%) | 68/161 (42.2%) |
DAS28-CRP | |||
 Patients achieving low disease activity: DAS28-CRP ≤ 3.2 | 101/259 (39.0%) | 166/415 (40.0%) | 84/157 (53.5%) |
 Patients achieving remission: DAS28-CRP < 2.6 | 60/259 (23.2%) | 101/415 (24.3%) | 59/157 (37.6%) |
CDAI | |||
 Patients achieving low disease activity: CDAI ≤ 10.0 | 93/259 (35.9%) | 172/416 (41.3%) | 92/161 (57.1%) |
 Patients achieving remission: CDAI ≤ 2.8 | 22/259 (8.5%) | 50/416 (12.0%) | 27/161 (16.8%) |
SDAI | |||
 Patients achieving low disease activity: SDAI ≤ 11.0 | 96/259 (37.1%) | 172/415 (41.4%) | 89/157 (56.7%) |
 Patients achieving remission: SDAI ≤ 3.3 | 22/259 (8.5%) | 53/415 (12.8%) | 29/157 (18.5%) |
Patients achieving Boolean remission | 6/260 (2.3%) | 12/416 (2.9%) | 12/161 (7.5%) |
Patients achieving HAQ-DI MCID (≥ 0.22) | 15/261 (5.7%) | 36/418 (8.6%) | 30/161 (18.6%) |